Merck & Co. Overview

  • Founded
  • 1891

Founded
  • Status
  • Public

  • Employees
  • 68,000

Employees
  • Stock Symbol
  • MRK

Stock Symbol
  • Investments
  • 73

  • Share Price
  • $92.42

  • (As of Friday Closing)

Merck & Co. General Information

Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Contact Information

Website
www.merck.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NYS
Primary Office
  • 2000 Galloping Hill Road
  • Kenilworth, NJ 07033
  • United States
+1 (908) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Merck & Co. Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$92.42 $91.17 $70.89 - $95.72 $234B 2.53B 12.5M $5.61

Merck & Co. Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 232,479,542 210,082,343 228,425,817 249,714,258
Revenue 53,978,000 48,704,000 41,518,000 39,121,000
EBITDA 20,013,000 17,863,000 10,121,000 11,100,000
Net Income 14,180,000 13,049,000 7,067,000 9,843,000
Total Assets 106,668,000 105,694,000 91,588,000 84,397,000
Total Debt 31,794,000 33,102,000 31,791,000 26,346,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Merck & Co. Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merck & Co.‘s full profile, request access.

Request a free trial

Merck & Co. Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabo
Pharmaceuticals
Kenilworth, NJ
68,000 As of 2021
00000000

000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat no
000000000000000
Brentford, United Kingdom
00000 As of 0000
000000000

000000

ng elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
000000000000000
Basel, Switzerland
000000 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Merck & Co. Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GlaxoSmithKline Corporation Brentford, United Kingdom 00000 000000000
00000000 Corporation Basel, Switzerland 000000 000000000000
00000000 000000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
000 000000 Corporate Backed or Acquired Monheim, Germany 0000 000000&0
000000 000000 Corporate Backed or Acquired Nashville, TN 000 000.00 000000000 000.00
You’re viewing 5 of 9 competitors. Get the full list »

Merck & Co. Patents

Merck & Co. Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100143383-A1 Oxgr1 agonists for use in therapies for metabolic disorders Abandoned 10-Dec-2008 00000000000
US-20110286916-A1 Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use Abandoned 20-Nov-2008 000000000
JP-2011530512-A Substituted dihydroisoquinolinones and isoquinolinedione derivatives as calcium channel blockers Withdrawn 06-Aug-2008 0000000000
US-20110136842-A1 Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers Abandoned 06-Aug-2008 0000000000
AU-2009279937-A1 Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers Abandoned 06-Aug-2008 C07D217/24
To view Merck & Co.’s complete patent history, request access »

Merck & Co. Executive Team (81)

Name Title Board Seat Contact Info
Robert Davis JD President & Chief Executive Officer
Juan Vera Chief Executive Officer (Market Access), Spain
Richard DeLuca Jr. Executive Vice President & President
Sanat Chattopadhyay Executive Vice President & President
Jannie Oosthuizen President & Senior Vice President
You’re viewing 5 of 81 executive team members. Get the full list »

Merck & Co. Board Members (25)

Name Representing Role Since
000000000 0000000 00 Self Board Member 000 0000
0000000 00000 00. Self Board Member 000 0000
0000 000000 Merck & Co. Board Member 000 0000
00000 000000 Self Board Member 000 0000
0000000 0000000 00 Merck & Co. Executive Chairman of the Board 000 0000
You’re viewing 5 of 25 board members. Get the full list »

Merck & Co. Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Merck & Co. Investments & Acquisitions (73)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (000000 11-May-2022 000000000 00.00 Buildings and Property
000000000 000 19-Nov-2021 0000000000 000.00 Drug Discovery 000000 00
0000000 00000 01-Apr-2021 0000000000 00.000 Drug Discovery 0000 00 0
00 0000000000 05-Feb-2021 00000 0000 000.00 Drug Discovery 00000 000
LifeMine 07-Jan-2021 Early Stage VC 0000 Drug Discovery
You’re viewing 5 of 73 investments and acquisitions. Get the full list »

Merck & Co. Subsidiaries (17)

Company Name Industry Location Founded
Tilos Therapeutics Biotechnology Lexington, MA 2016
000 00000000 0000 Corporate Venture Capital Cambridge, MA 0000
00000 000000000000 Drug Discovery Geneva, Switzerland 0000
0000000 0000000000 Pharmaceuticals Dallas, TX 0000
00000 000000 00000 Corporate Venture Capital Kenilworth, NJ 0000
You’re viewing 5 of 17 subsidiaries. Get the full list »

Merck & Co. Exits (24)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 000000000000 17-Sep-2020 00000 00000 00 0000 Completed
  • 9 buyers
00000000 000000000 24-Jun-2020 00000 00000 00 000.00 Completed
  • 7 buyers
0000000 25-Jul-2018 00000 00000 00 00000 Completed
  • 20 buyers
00000000 0000 0000 01-Aug-2016 00000 00000 00 0000 Completed
  • 4 buyers
Alector 07-Jan-2016 Later Stage VC 000.00 Completed
  • 12 buyers
You’re viewing 5 of 24 exits. Get the full list »